Shareholders’ (Deficiency) Equity (Tables)

12 Months Ended

Dec. 31, 2024

Shareholders’ (Deficiency) Equity [Abstract]

Schedule of Summary of Share Option Plans

A summary of the status of options under the Company’s share option plans as of December 31, 2024 and changes during the relevant period ended on that date is presented below:

	For the year ended December 31, 2024
	Number of options			Weighted average exercise price		Aggregate intrinsic value		Weighted average remaining contractual life (years)
Outstanding at beginning of year		10,520,774		$	5.03	$	2,264		7.08
Granted		4,170,370		$	3.60
Exercised		(22,602	)	$	1.10	$	39
Forfeited		(218,892	)	$	5.38
Outstanding at end of period		14,449,650		$	4.62	$	2,964		6.92
Exercisable options		9,563,187		$	4.81	$	2,430		6.15

Schedule of Summary of RSUs Under the Plan

A summary of the status of RSUs under the Plan as of December 31, 2024 and changes during the relevant period ended on that date is presented below:

	RSUs
	Unvested RSUs			Weighted-average grant date fair value per share
Outstanding at beginning of year		813,268		$	5.68
Granted		796,127		$	2.88
Vested		(687,356	)	$	4.50
Forfeited		(64,140	)	$	3.84
Outstanding at end of year		857,899		$	4.24

Schedule of Total Equity-Based Compensation Expense

The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2022, 2023 and 2024, was comprised as follows:

	Year ended December 31,
	2022		2023		2024
Research and development	$	4,289	$	5,073	$	6,454
Marketing expenses		210		474		753
General and administrative		2,249		2,379		2,709
Total share-based compensation expense	$	6,748	$	7,926	$	9,916